Value-Based Pricing for Drugs With Uncertain Clinical Benefits
This is the title of a recent paper by Jiao et al. (2025). Previous studies (e.g., Goldman et al. 2013, Goldman et al. 2023) have argued for a 3-part pricing model. Under a 3-part pricing model, drugs would come to market quickly under accelerated approval with a relatively lower price. As clinical trials and other…